FDA cancellation of the April 9 Peripheral and Central Nervous System Drugs Advisory Committee meeting will "allow the agency to continue its review" of the mecasermin NDA, Cephalon said. FDA said that "further analyses of the data by the agency and sponsor were not complete and ready for discussion." The agency has not indicated if the meeting will be rescheduled. The meeting would have been the committee's third to discuss Myotrophin for amyotrophic lateral sclerosis. The user fee goal date for Myotrophin is May 11...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth